US FDA approves expanded use of BeiGene's blood cancer drug-February 2024-www.financetom.com

US FDA approves expanded use of BeiGene's blood cancer drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves expanded use of BeiGene's blood cancer drug

Mar 7, 2024 12:57 PM

March 7 (Reuters) - The U.S. Food and Drug

Administration has granted accelerated approval for the expanded

use of BeiGene's ( BGNE ) combination drug to treat certain

patients with a type of blood cancer, the health regulator said

on Thursday.

Previous page： --Apple Asks to Join Google's Antitrust Online Search Case Next page： Palantir Stock Is Trading At All-Time Highs: What's Going On?

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Apple Asks to Join Google's Antitrust Online Search Case

Dec 24, 2024

11:48 AM EST, 12/24/2024 (MT Newswires) -- Price: 196.82, Change: +0.83, Percent Change: +0.42 ...

Palantir Stock Is Trading At All-Time Highs: What's Going On?

Dec 24, 2024

Palantir Technologies Inc ( PLTR ) shares are hitting new highs on Tuesday. Here’s a look at what’s going on. What To Know: Palantir ( PLTR ) shares are up more than 380% since the start of the year, driven largely by the company’s positioning in the AI space. The rally in Palantir ( PLTR ) shares accelerated at the...

Why Biotechnology Company Carmell Shares Are Seeing Blue Skies Tuesday?

Dec 24, 2024

Carmell Corporation ( CTCX ) shares are trading higher after it entered into a securities purchase agreement with new and existing investors. The agreement involves the issuance and sale of 8,065,210 shares of common stock and an equal number of five-year warrants, both priced at $0.23 per share, in a private placement. The transaction is expected to generate gross proceeds...

Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts

Dec 24, 2024

Achilles Therapeutics plc ( ACHL ) shares are trading higher on Tuesday after the company announced a $12 million deal with AstraZeneca PLC ( AZN ) and plans to cut jobs. The agreement involves the transfer of the commercial license for data and tumor samples from Achilles’ TRACERx Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca ( AZN ). The...